Results 211 to 220 of about 1,865,175 (347)
We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto +8 more
wiley +1 more source
To start or not to start? An exploratory study of work meaningfulness among start-up co-founders. [PDF]
Dirik D, Özdoğan B.
europepmc +1 more source
Early Career Perspectives from Large Pharma, Software, and Start-up Companies. [PDF]
Ruggiu F, Bannan C, Bootsma A.
europepmc +1 more source
Liquid biopsy enables minimally invasive, real‐time molecular profiling through analysis of circulating biomarkers in biological fluids. This Perspective highlights the importance of training pathologists through integrative educational programs, such as the European Masters in Molecular Pathology, to ensure effective and equitable implementation of ...
Marius Ilié +13 more
wiley +1 more source
What motivates start-up entrepreneurs? Exploring the role of human values in success. [PDF]
Curtin E, Coelho GLH, Hanel PHP.
europepmc +1 more source
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice +16 more
wiley +1 more source
College students' entrepreneurship education path and management strategy of start-up enterprises using causal attribution theory. [PDF]
Liu Q, An X, Chen W.
europepmc +1 more source
Tax Treatment of High-Tech Start-Up Costs [PDF]
Hostetter, June (Yun), CPA
core +2 more sources
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source

